Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| GI Biome | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
This study aims to investigate the effects of probiotics named GI Biome #7 on the gut microbiome and muscle strength in older adults aged 60 years or older.
This study is a double-blind, randomized controlled trial. A total of 60 healthy adults aged 60 years or older will be recruited, and they will be randomly assigned to the intervention group or the control group. The intervention group will be given GI Biome #7 pills, and the control group will be given the placebo pills for four weeks. The participants will visit the research laboratory four times as follows: A day before starting to take the pills, two weeks later after starting to take the pills, the last day of taking the pills, and four weeks later after the end of taking the pills. Participants' stool, blood, and urine will be sampled every visit, and grip strength and body composition will also be checked.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| GI Biome #7 | Experimental | The intervention consists of daily administration of probiotics GI Biome #7 for four weeks. |
|
| Placebo | Placebo Comparator | The placebo consists of daily administration of the placebo pills made up of 100% maltodextrin for four weeks. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| GI Biome #7 | Dietary Supplement | It comprises probiotics (Lactobacillus fermentum, Lactobacillus acidophilus, Lactobacillus plantarum, and Bifidobacterium animalis ssp. lactis) and prebiotics (vitamin B2., Korean red ginseng, and etc.). The administration dosage of probiotics is 5×10^8 CFU/day. |
| Measure | Description | Time Frame |
|---|---|---|
| Hand Grip Strength Change | Change from baseline hand grip strength at 4 weeks | 4 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Bacteroidetes/Firmicutes Ratio Change | Change from baseline Bacteroidetes/Firmicutes ratio in gut microbiome at 4 weeks | 4 weeks |
| Fasting blood glucose | Change from baseline fasting blood glucose at 4 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Walking speed | The time to walk a 10-m distance will be measured. | 0, 2, 4, 8 weeks |
| Gut quotient | Gut quotient measurement scales will be asked using questionnaires. The minimum and maximum values are 0 and 100, respectively. Higher scores are related to worse gut quotient. |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Yun-Chul Hong, MD, PhD | Seoul National University | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Seoul National University College of Medicine | Seoul | 03080 | South Korea |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D018908 | Muscle Weakness |
| ID | Term |
|---|---|
| D009135 | Muscular Diseases |
| D009140 | Musculoskeletal Diseases |
| D020879 | Neuromuscular Manifestations |
| D009461 | Neurologic Manifestations |
Not provided
Not provided
A double-blind, randomized controlled trial
Not provided
Not provided
Not provided
|
| Placebo | Dietary Supplement | The placebo consists of daily administration of the placebo pills made up of 100% maltodextrin for four weeks. |
|
| 4 weeks |
| 0, 2, 4, 8 weeks |
| IGF-1 | IGF-1 will be quantified from the participants' serum samples. | 0, 2, 4, 8 weeks |
| Myostatin | Myostatin will be quantified from the participants' serum samples. | 0, 2, 4, 8 weeks |
| 8-OHdG | 8-OHdG will be quantified from the participants' serum samples. | 0, 2, 4, 8 weeks |
| Fecal acetate level | Acetate level (short-chain fatty acid) will be measured from the participants' stool. | 0, 2, 4, 8 weeks |
| Fecal butyrate level | Butyrate level (short-chain fatty acid) will be measured from the participants' stool. | 0, 2, 4, 8 weeks |
| Fecal propionate level | Propionate level (short-chain fatty acid) will be measured from the participants' stool. | 0, 2, 4, 8 weeks |
| Fecal calproate level | Calproate level (short-chain fatty acid) will be measured from the participants' stool. | 0, 2, 4, 8 weeks |
| Fecal valerate level | Valerate level (short-chain fatty acid) will be measured from the participants' stool. | 0, 2, 4, 8 weeks |
| D009422 | Nervous System Diseases |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D012816 | Signs and Symptoms |